Quick Reference: Screening for Chloroquine & Hydroxychloroquine (Plaquenil) Retinopathy

Sep 23, 2015
2 min read

Dr. Corte provides a quick reference guide based on the AAO's updated screening guidelines for chloroquine and hydroxychloroquine (Plaquenil) retinopathy.


As optometrists, it is important that we are aware of the possible ocular complications that can occur from the use of high risk medications.

Patients starting chloroquine (CQ) or hydroxychloroquine (HCQ; i.e. Plaquenil) should have a baseline examination that serves as a reference point, as well as to rule out any preexisting maculopathies.

While most rheumatologists are now routinely prescribing their patients 400 mg of HCQ (or 250 mg CQ) daily for the management of conditions like systemic lupus erythematosus and rheumatoid arthritis, individuals of short stature often have their dosage determined off of their ideal body weight to avoid overdosing.

Annual screening should begin after 5 years of medication use unless the patient has any of the unusual risk factors described below.

Unusual risk factors that increase the risk of CQ or HCQ Retinopathy:1

  • Total cumulative dose >460 g of CQ or > 1000 g of HCQ
  • Daily Dose > 250 mg/day CQ or >400 mg/day HQC
  • Age, kidney dysfunction, liver dysfunction, retinal disease or maculopathy

American Academy of Ophthalmology Recommended Screening:1

  • Required:

    • Complete ocular health examination including a dilated retinal assessment

      • Concern: Preexisting retinal disease and bullseye maculopathy
    • 10-2 visual field

      • Concern: Paracentral scotomas with decreased foveal sensitivity
  • One (or more) of the following tests: 

    • Spectral domain OCT of the Macular

      • Concern: Parafoveal thinning of photoreceptor layers and/or loss of the inner-segment/outer-segment junction
    • Multifocal ERG

      • Concern: Decreased parafoveal waveform amplitudes
    • Fundus autofluorescence

      • Concern: Parafoveal hyperfluorescence

It's critical to educate your patients on the risk of toxicity and the importance of screening. If early changes and/or visual loss is detected, consult with your patient's prescribing doctor immediately, as they should discontinue the medication and consider alternative therapies.


  1. M.F. Marmor, U. Kellner, T.Y. Lai, et al., Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy, Ophthalmology, 118 (2011), pp. 415–422
About Ryan Corte, OD

Ryan Corte attended The Ohio State University College of Optometry and graduated in 2012. He completed an Optometric Residency in Primary Care and Ocular Disease at the Illinois College of Optometry in 2013. He currently splits time between Modern Eye Care and Premier Family Eye Care in metropolitan Charlotte, NC. Ryan is a former Executive President of the American Optometric Student Association. He also serves on the Student and New Graduate Committee of the American Optometric Association.